Abstract. Cardiac fibrosis is considered an important pathological mechanism in the progression of cardiac remodeling and heart failure. Astragaloside IV (AsIV) is a major active ingredient in Astragalus membranaceus. In a preliminary experiment, it was demonstrated that this naturally occurring substance exhibited cardioprotective effects via preventing cardiomyocyte hypertrophy and apoptosis. The present study aimed to investigate the effects of AsIV on β-adrenergic receptor (β-AR)-mediated cardiac fibrosis, and the associated mechanism. Cell Counting Kit-8 (CCK-8) assay was used to examine the proliferation of rat cardiac fibroblast (CF) cultures. Collagen I secretion was detected by ELISA. Dihydroethidium was used to determine intracellular ROS levels. Western blotting was used to examine the expression level of total and phosphorylated mitogen-activated protein kinases (MAPKs). In the present study, the effects of AsIV on β-adrenergic receptor (β-AR) -mediated cardiac fibrosis were investigated, and the associated mechanism was revealed. Isoprenaline (ISO) is a selective β-AR agonist, and treatment with AsIV significantly inhibited (ISO)-triggered cardiac fibroblast proliferation and type I collagen synthesis. In addition, ISO resulted in a significant elevation of reactive oxygen species (ROS) levels and phosphorylation of the three profibrotic MAPKs, namely extracellular signal-regulated kinase, p38MAPK and c-Jun N-terminal kinase. AsIV effectively reversed the aforementioned ISO-induced alterations. In addition, N-acetylcysteine, a typical ROS scavenger, mimicked the inhibitory effects of AsIV on MAPK activation. The present study demonstrated that AsIV may inhibit ISO-induced cardiac fibrosis by suppressing ROS-mediated MAPK activation.
Introduction
Cardiac hypertrophy and fibrosis are two important pathological alterations that occur during the progressive development of heart failure (1, 2) . Cardiac fibrosis refers to the excessive accumulation of extracellular matrix (ECM) and fibroblast deposition in the heart (3). Cardiac fibrosis is important in pathological cardiac remodeling and correlates with the occurrence of several fatal heart diseases, including heart failure, severe arrhythmia and sudden cardiac death (3, 4) . It has previously been demonstrated that isoprenaline (ISO) is important in cardiac fibrosis via increasing and/or activating several effector molecules, including reactive oxygen species (ROS), p38 mitogen-activated protein kinase (p38MAPK) and extracellular signal-regulated kinase (ERK) (3, 5) .
Astragaloside IV (AsIV) is one of the major active ingredients of the plant Astragalus membranaceus, which is referred to as HuangQi in Chinese. As an important Qi-invigorating medicinal herb, A. membranaceus is extensively used in traditional Chinese medicine for the treatment of cardiovascular diseases, hepatitis, and kidney and skin diseases (2, 6, 7) . Chemically, AsIV is a cycloartane triterpene saponin with a well-defined molecular formula, the chemical structure of which is presented in Fig. 1 . It has previously been demonstrated that AsIV exhibits cardioprotective effects via its antioxidative and anti-inflammatory properties (8, 9) . In addition, AsIV has been reported to improve cardiac function via the inhibition of cardiomyocyte hypertrophy and apoptosis (6, 8) . However, the function of AsIV in cardiac fibrosis remains to be fully elucidated, with only one previous study, to the best of our knowledge, currently available reporting its anti-fibrotic effect in coxsackievirus-induced cardiomyopathy (10) . Therefore, the present study aimed to examine whether AsIV possesses antifibrotic activity under ISO stimulation and aimed to elucidate the associated underlying molecular mechanism. CF proliferation assay. CFs were digested with 0.25% trypsin and ethylene diamine tetraacetic acid, then cultured in 96-well plates in the presence and absence of 100 µM AsIV (>98% purity; Nanjing Jingzhu Bio-Technology Co., Ltd., Nanjing, China) or the specific inhibitor of JNK, SP600125 (10 µΜ, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) for 30 min prior to treatment with 10 µM ISO (Sigma-Aldrich; Merck KGaA). Following incubation for 24 h in a humidified atmosphere of 5% CO 2 , at 37˚C, the supernatant was removed, and 100 µl DMEM containing 10 µl Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to each well for a further 4 h at 37˚C. The optical density was measured at a wavelength of 450 nm using an automated ELISA plate reader (Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Materials and methods

Animals
ELISA. The secretion of collagen type I by CFs was measured using a commercial ELISA kit (catalog no. CSB-E 12732r; Cusabio Biotech Co., Ltd., Wuhan, China) according to the manufacturer's protocol.
Measurement of intracellular ROS. Dihydroethidium (DHE; Molecular Probes; Thermo Fisher Scientific, Inc.) was used to determine intracellular ROS levels in cultured CFs. Briefly, CFs were incubated with 10 µM DHE for 30 min at 37˚C in the dark. Cells were then washed 3 times with phosphate-buffered saline (PBS) to remove unincorporated dye. CFs loaded with DHE were then treated with 100 µM AsIV for 30 min, followed by treatment with 10 µM ISO for an additional 30 min. ROS levels were subsequently analyzed using an inverted fluorescence microscope (Leica Microsystems GmbH, Wetzlar, Germany).
Western blotting. 
Results
AsIV attenuates ISO-induced CF proliferation and type I collagen synthesis.
To evaluate the effects of AsIV on ISO-induced cardiac fibrosis, CF proliferation and type I collagen levels were examined. As presented in Fig. 2A , CF proliferation was significantly increased upon ISO stimulation for 24 h. Treatment with AsIV (100 µM) inhibited ISO-triggered CF proliferation. Increased collagen synthesis in ISO-treated cultured CFs was also significantly decreased with application of AsIV (Fig. 2B) .
JNK mediates ISO-induced CF proliferation and type I collagen synthesis.
The MAPK signaling pathway is composed of ERK, p38MAPK and JNK. Previous studies have demonstrated that ERK and p38MAPK are required for β-adrenergic activation of CF proliferation (3, 5, 11) . However, it remains to be elucidated whether JNK is involved in this process. To investigate this, CF proliferation and type I collagen synthesis were measured following 24 h treatment with ISO in the absence or presence of the JNK inhibitor, SP600125. As presented in Fig. 3A and B, ISO-induced CF proliferation and collagen synthesis were significantly decreased by pretreatment with SP600125, indicative of a key role of JNK in ISO-induced cardiac fibrosis.
AsIV decreases ISO-induced ROS generation in CFs.
AsIV is a potent antioxidant (12,13). Furthermore, ROS is important in ISO-induced cardiac fibrosis (3, 14) . The present study therefore examined the effects of AsIV on ROS production in CFs. As presented in Fig. 4 , ISO-induced ROS production was effectively decreased by pretreatment with 100 µM AsIV.
AsIV and NAC attenuate ISO-induced phosphorylation of MAPK family members.
In view of the important role of MAPK molecules in ISO-induced cardiac fibrosis, the present study investigated the effects of AsIV on MAPK activation. As presented in Fig. 5 , ISO activated the three MAPKs, ERK, p38MAPK and JNK. Conversely, AsIV inhibited the activation of these three MAPKs. In addition, NAC, which is a typical ROS scavenger, exhibited similar inhibitory effects to those demonstrated by AsIV on MAPK activation.
Discussion
The present study demonstrated that AsIV may protect against ISO-induced CF proliferation and type I collagen synthesis. The underlying mechanism involved inhibition of ROS production and the resultant downregulation of MAPK signaling. To the best of our knowledge, this study is the first to reveal the antifibrotic effect, and associated mechanism, of AsIV in response to ISO stimulation. Cardiac fibrosis is characterized by enhanced CF proliferation and excessive production and deposition of the ECM, of which ~85% is composed of type I collagen (15, 16) . This consequently results in myocardial stiffness, impaired diastolic function and cardiac failure (17, 18) . Antifibrotic mechanisms are therefore regarded as effective therapeutic strategies for the treatment of various cardiovascular diseases. It has previously been demonstrated that AsIV exerts therapeutic effects on fibrosis in several disorders, including chronic kidney disease (19) , systemic sclerosis (20) , liver fibrosis (21), and coxsackievirus B3-induced cardiomyopathy (10) . However, its effect on β-adrenergic receptor-induced cardiac fibrosis remains to be fully elucidated. The present study therefore investigated the effects of AsIV on ISO-mediated cardiac fibrosis and the associated signaling transduction. The results demonstrated that pretreatment with AsIV significantly inhibited ISO-induced CF proliferation and type I collagen synthesis, thus suggesting that AsIV is a promising agent for the prevention and treatment of cardiac fibrosis under increased sympathetic drive.
Oxidative stress is important in the development and progression of diverse cardiac disorders, including cardiac fibrosis (14) , hypertrophy (22) , apoptosis (23), inflammation (24) and resultant heart failure (25, 26) . It has previously been demonstrated that ROS may modulate ECM remodeling by mediating CF function and stimulating collagen turnover (26) . Antioxidative mechanisms may prevent numerous adverse cardiovascular events, including cardiac fibrosis. GKT137831 (14) , oleanolic acid (27), 3,3'-diindolymethane (28) and magnolol (29) , have been demonstrated to attenuate cardiac fibrosis via antioxidative bioactivity. The antioxidative capacity of AsIV has increasingly been identified by previous studies (12, 13) . Data from the present study revealed that application of AsIV effectively suppressed ROS accumulation. It was therefore concluded that the antifibrotic effects of AsIV may depend on its antioxidative activity.
One important consequence of oxidative stress is the phosphorylation of MAPK proteins, including ERK, p38MAPK and JNK. MAPK activation has been observed in cardiac fibrosis in response to oxidative stress triggered by angiotensin II (30) (31) (32) (33) . In addition, it has been suggested that ISO induces cardiac fibrosis via activation of p38MAPK and ERK (3, 5) . To elucidate the involvement of JNK in ISO-induced cardiac fibrosis, the effect of SP600125, a selective inhibitor of JNK, was investigated. The results indicated that SP600125 inhibited CF proliferation and type I collagen synthesis, suggesting a similarly indispensible role of JNK in ISO-triggered cardiac fibrosis, as that observed of ERK and p38MAPK. Furthermore, data from the present study revealed that the phosphorylation of the three pro-fibrotic MAPK molecules was abrogated by application of AsIV. In addition, the inhibitory effects of AsIV on MAPK signaling were mimicked by the selective ROS inhibitor, NAC; thus, indicating that AsIV inhibits MAPK signaling in a ROS-dependent manner. ### P<0.001, vs. ISO group. Magnification, x200. ISO, isoprenaline; ROS, reactive oxygen species; AsIV, astragaloside IV; CFs, cardiac fibroblasts; DHE, dihydroethidium.
In conclusion, the present study demonstrated that AsIV effectively inhibited ISO-induced CF proliferation and type I collagen synthesis via attenuation of ROS-mediated MAPK signaling activation. These findings may aid to further elucidate the protective role and underlying molecular mechanism of AsIV in the cardiovascular system. Figure 5 . Effects of AsIV and NAC on ISO-induced activation of the MAPK family. Activation was measured by analyzing the expression levels of phosphorylated proteins, as detected by western blotting. A total of 100 µM AsIV was added to 10 µM ISO-induced CFs to measure activation of ERK, p38MAPK and JNK MAPK signaling pathways. This was repeated with the addition of 10 mM NAC to 10 µM ISO-induced CFs. Data are expressed as the mean ± standard error of the mean from three independent experiments. ** P<0.01 vs. control group; ## P<0.01 vs. ISO group. ERK, extracellular signal-regulated kinase; p38MAPK, p38 mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; p, phosphorylated; AsIV, astragaloside IV; CFs, cardiac fibroblasts; NAC, N-acetylcysteine; ISO, isoprenaline.
